Pre-exposure (PrEP)
Pre-exposure Prophylaxis (PrEP)
CROI 2017: STI Prophylaxis in PrEP Users Reduces Syphilis and Chlamydia, but Not Gonorrhea
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 15 February 2017 00:00
- Written by Gus Cairns
Use of the antibiotic doxycycline as on-demand post-exposure prophylaxis by men who have sex with men taking part in the Ipergay HIV PrEP trial produced a 70% drop in chlamydia infections and a 73% drop in syphilis, but no reduction in gonorrhea, according to a late-breaking report at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.
Hope Overshadowed -- The National HIV PrEP Summit
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 31 January 2017 00:00
- Written by Gus Cairns
The U.S. National HIV PrEP Summit, which took place in early December in San Francisco, was designed as an event of celebration and hope. Its structure, its speakers, even the way the plenary room was designed and the way the speakers dressed, all conveyed one message: we are all in this together, and pre-exposure prophylaxis (PrEP) really is the game-changer we have been looking for.
U.K.'s Largest Sexual Health Clinic Saw 40% Drop in New HIV Diagnoses in 2016
- Details
- Category: HIV Prevention
- Published on Tuesday, 27 December 2016 00:00
- Written by Gus Cairns
The clinic at 56 Dean Street in Soho, central London, the largest sexual health clinic in the U.K., saw an unprecedented 40% drop in new HIV diagnoses this year. Another clinic, the Mortimer Market Centre a mile away from Dean Street, has seen an even bigger 50% fall.
No New HIV Infections in Northern California Kaiser PrEP Program, but STI Rates Rising
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 24 January 2017 00:00
- Written by Liz Highleyman
No new HIV infections have been seen among nearly 1000 people who started Truvada for pre-exposure prophylaxis (PrEP) at Kaiser Permanente Northern California, according to a report in the December 15, 2016, Journal of Acquired Immune Deficiency Syndromes. The most recent analysis shows, however, that incidence of chlamydia and gonorrhea is high, suggesting that sexually transmitted infection (STI) testing may be needed quarterly rather than every 6 months.
First Large Study of Long-Acting Injectable for HIV Prevention Now Underway
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 27 December 2016 00:00
- Written by HIVandHepatitis.com
The National Institutes of Health and industry collaborators last week launched a large-scale clinical trial to test long-acting injectable cabotegravir for HIV prevention. Study HPTN 083 will compare cabotegravir injections administered every 8 weeks versus once-daily oral tenofovir/emtricitabine (Truvada) pre-exposure prophylaxis (PrEP). Results are expected in 2021.
More Articles...
- 4. PrEP Use Widens, But Disparities Remain
- HIVR4P 2016: The Long Tail Problem -- Injectable PrEP Trial To Be Extended Due to Drug Persistence
- IDWeek 2016: HIV+ Men and Men on PrEP in Boston See Large Increase in Sexually Transmitted Infections
- HIV Glasgow: Tests of Online PrEP Purchases Find No Fakes and Adequate Drug Levels
Web Design and Development by